{
  "links": "https://www.ycombinator.com/companies/aoa-dx-inc",
  "name": "AOA Dx",
  "headline": "Blood Test for Early Detection of Ovarian Cancer",
  "batch": "S21",
  "description": "AOA Dx is developing the next frontier in early-stage cancer detection for women through our pioneering work in glycolipids and proprietary biomarker technology.",
  "activity_status": "Active",
  "website": "https://www.aoadx.com/",
  "founded_date": 2020.0,
  "team_size": 25.0,
  "location": "Denver, CO",
  "group_partner": "Jared Friedman",
  "group_partner_yc": "https://www.ycombinator.com/people/jared-friedman",
  "company_linkedin": null,
  "company_twitter": null,
  "tags": "industry:healthcare; industry:diagnostics; industry:women's-health",
  "founders": [
    {
      "name": "Oriana Papin-Zoghbi, Founder",
      "description": "CEO & Co-Founder AOA Dx Inc. Passionate about Women's Health.",
      "linkedin": "https://www.linkedin.com/in/orianazh/"
    },
    {
      "name": "Alex Fisher, Founder/COO",
      "description": "Chief Operating Officer & Co-Founder of AOA Dx. Passion about improving women's health.",
      "linkedin": "https://www.linkedin.com/in/alexanderjfisher/"
    },
    {
      "name": "Anna Jeter, Founder",
      "description": "Chief Business Officer & Co-Founder",
      "linkedin": "https://www.linkedin.com/in/anna-milik-jeter-88036329/"
    }
  ],
  "status": true,
  "markdown": "raw_markdown=\"[Skip to content](https://www.aoadx.com/<#content>)\\n[ ![](https://aoadx.com/wp-content/uploads/2022/11/logo-aoa.png) ](https://www.aoadx.com/</>)\\n  * [About](https://www.aoadx.com/<#!>)\\n    * [About Us](https://www.aoadx.com/<https:/aoadx.com/about-us/>)\\n    * [Our Team](https://www.aoadx.com/<https:/aoadx.com/our-team/>)\\n  * [Technology](https://www.aoadx.com/<#!>)\\n    * [GlycoLocate™](https://www.aoadx.com/<https:/aoadx.com/glycolocate/>)\\n    * [AKRIVIS GD™](https://www.aoadx.com/<https:/aoadx.com/akrivis-gd/>)\\n  * [Publications](https://www.aoadx.com/<https:/aoadx.com/publications-aoa/>)\\n  * [News](https://www.aoadx.com/<https:/aoadx.com/news/>)\\n  * [Careers](https://www.aoadx.com/<https:/aoadx.com/careers-opportunities/>)\\n  * [Contact](https://www.aoadx.com/<https:/aoadx.com/contact/>)\\n\\n\\n[![AOA-logo-white](https://aoadx.com/wp-content/uploads/2022/11/AOA-logo-white.png)](https://www.aoadx.com/<https:/aoadx.com>)X\\n# The future of early cancer detection is now\\nA ground breaking AI-enabled early detection platform focused on women’s health\\n# The future of early cancer detection is now\\u200b\\nA ground breaking AI-enabled early detection platform focused on women’s health\\n### GlycoLocate™\\nOur revolutionary multi-omics platform is paving the way for life-saving early cancer detection\\n[ LEARN MORE ](https://www.aoadx.com/<https:/aoadx.com/glycolocate/>)\\n### AKRIVIS GD™\\nA novel blood test harnessing the power of AI and multi-omics to detect early-stage ovarian cancer\\n[ LEARN MORE ](https://www.aoadx.com/<https:/aoadx.com/akrivis-gd/>)\\n![](https://aoadx.com/wp-content/uploads/2022/11/akrivis-GD.png)\\n#### Welcome to the future\\n## GlycoLocate™: An AI Enabled Early Detection Cancer Platform \\nAOA Dx is pioneering the field of lipidomics through the utilization of tumor marker gangliosides, the next class of biomarkers in early cancer detection. AOA Dx is developing the first and only technology utilizing these markers and other complimentary biomarkers with data science, providing remarkable insights into early cancer detection.\\n## Who We Are\\nDevoted to innovation in women’s health, AOA Dx is a team of industry experts and entrepreneurs committed to bringing impactful and cost-effective medical technologies from research and development into the hands of providers and patients.\\n[ LEARN MORE ](https://www.aoadx.com/<https:/aoadx.com/about/>)\\n![](https://aoadx.com/wp-content/uploads/2023/12/pic.webp)\\nDo you want to be a part of transforming women's health through early cancer detection? \\n# Join us on our mission\\nWe’re looking for teammates dedicated to raising the bar in women’s health.\\n[ Career Opportunities ](https://www.aoadx.com/<https:/aoadx.com/careers-opportunities/>)\\n## Featured In\\n![](https://aoadx.com/wp-content/uploads/2022/12/41591f_f942098ca7614a498a49767482695cfcmv2-1.png)\\n![](https://aoadx.com/wp-content/uploads/2023/12/bloomberg.png)\\n![](https://aoadx.com/wp-content/uploads/2022/12/41591f_1adbd42e1a5a4d038b664963fca92e2fmv2.png)\\n![](https://aoadx.com/wp-content/uploads/2022/12/Business_Insider_Logo.svg.png)\\n![](https://aoadx.com/wp-content/uploads/2022/12/41591f_3794b7c3fa134343a45534e92b8ae237mv2.png)\\n![](https://aoadx.com/wp-content/uploads/2022/12/41591f_80cabe0f77934601846574966ef57f24mv2.png)\\n## Get in Touch\\nSEND\\n##### Legal\\nCopyright 2020 – 2025 \\n[Privacy Policy](https://www.aoadx.com/<https:/aoadx.com/privacy-policy/>)\\n##### Contact\\ninfo@aoadx.com\\npress@aoadx.com\\ncareers@aoadx.com\\n6860 Broadway, Denver CO 80221\\n##### Follow\\n[ Instagram ](https://www.aoadx.com/<https:/instagram.com/aoa_dx>) [ Linkedin ](https://www.aoadx.com/<https:/www.linkedin.com/company/26216536>) [ Twitter ](https://www.aoadx.com/<https:/twitter.com/AOA_Dx>)\\n[Website by Sungraphic](https://www.aoadx.com/<https:/sungraphic.com/>)\\n\" markdown_with_citations=\"Skip to content⟨1⟩\\n ![⟨2⟩ ](https://www.aoadx.com/</>)\\n  * About⟨3⟩\\n    * About Us⟨4⟩\\n    * Our Team⟨5⟩\\n  * Technology⟨3⟩\\n    * GlycoLocate™⟨6⟩\\n    * AKRIVIS GD™⟨7⟩\\n  * Publications⟨8⟩\\n  * News⟨9⟩\\n  * Careers⟨10⟩\\n  * Contact⟨11⟩\\n\\n\\n![AOA-logo-white⟨12⟩](https://www.aoadx.com/<https:/aoadx.com>)X\\n# The future of early cancer detection is now\\nA ground breaking AI-enabled early detection platform focused on women’s health\\n# The future of early cancer detection is now\\u200b\\nA ground breaking AI-enabled early detection platform focused on women’s health\\n### GlycoLocate™\\nOur revolutionary multi-omics platform is paving the way for life-saving early cancer detection\\n LEARN MORE ⟨6⟩\\n### AKRIVIS GD™\\nA novel blood test harnessing the power of AI and multi-omics to detect early-stage ovarian cancer\\n LEARN MORE ⟨7⟩\\n![](https://aoadx.com/wp-content/uploads/2022/11/akrivis-GD.png)\\n#### Welcome to the future\\n## GlycoLocate™: An AI Enabled Early Detection Cancer Platform \\nAOA Dx is pioneering the field of lipidomics through the utilization of tumor marker gangliosides, the next class of biomarkers in early cancer detection. AOA Dx is developing the first and only technology utilizing these markers and other complimentary biomarkers with data science, providing remarkable insights into early cancer detection.\\n## Who We Are\\nDevoted to innovation in women’s health, AOA Dx is a team of industry experts and entrepreneurs committed to bringing impactful and cost-effective medical technologies from research and development into the hands of providers and patients.\\n LEARN MORE ⟨13⟩\\n![](https://aoadx.com/wp-content/uploads/2023/12/pic.webp)\\nDo you want to be a part of transforming women's health through early cancer detection? \\n# Join us on our mission\\nWe’re looking for teammates dedicated to raising the bar in women’s health.\\n Career Opportunities ⟨10⟩\\n## Featured In\\n![](https://aoadx.com/wp-content/uploads/2022/12/41591f_f942098ca7614a498a49767482695cfcmv2-1.png)\\n![](https://aoadx.com/wp-content/uploads/2023/12/bloomberg.png)\\n![](https://aoadx.com/wp-content/uploads/2022/12/41591f_1adbd42e1a5a4d038b664963fca92e2fmv2.png)\\n![](https://aoadx.com/wp-content/uploads/2022/12/Business_Insider_Logo.svg.png)\\n![](https://aoadx.com/wp-content/uploads/2022/12/41591f_3794b7c3fa134343a45534e92b8ae237mv2.png)\\n![](https://aoadx.com/wp-content/uploads/2022/12/41591f_80cabe0f77934601846574966ef57f24mv2.png)\\n## Get in Touch\\nSEND\\n##### Legal\\nCopyright 2020 – 2025 \\nPrivacy Policy⟨14⟩\\n##### Contact\\ninfo@aoadx.com\\npress@aoadx.com\\ncareers@aoadx.com\\n6860 Broadway, Denver CO 80221\\n##### Follow\\n Instagram ⟨15⟩  Linkedin ⟨16⟩  Twitter ⟨17⟩\\nWebsite by Sungraphic⟨18⟩\\n\" references_markdown='\\n\\n## References\\n\\n⟨1⟩ https://www.aoadx.com/<#content>: Skip to content\\n⟨2⟩ https://aoadx.com/wp-content/uploads/2022/11/logo-aoa.png:  ![\\n⟨3⟩ https://www.aoadx.com/<#!>: About\\n⟨4⟩ https://www.aoadx.com/<https:/aoadx.com/about-us/>: About Us\\n⟨5⟩ https://www.aoadx.com/<https:/aoadx.com/our-team/>: Our Team\\n⟨6⟩ https://www.aoadx.com/<https:/aoadx.com/glycolocate/>: GlycoLocate™\\n⟨7⟩ https://www.aoadx.com/<https:/aoadx.com/akrivis-gd/>: AKRIVIS GD™\\n⟨8⟩ https://www.aoadx.com/<https:/aoadx.com/publications-aoa/>: Publications\\n⟨9⟩ https://www.aoadx.com/<https:/aoadx.com/news/>: News\\n⟨10⟩ https://www.aoadx.com/<https:/aoadx.com/careers-opportunities/>: Careers\\n⟨11⟩ https://www.aoadx.com/<https:/aoadx.com/contact/>: Contact\\n⟨12⟩ https://aoadx.com/wp-content/uploads/2022/11/AOA-logo-white.png: ![AOA-logo-white\\n⟨13⟩ https://www.aoadx.com/<https:/aoadx.com/about/>:  LEARN MORE \\n⟨14⟩ https://www.aoadx.com/<https:/aoadx.com/privacy-policy/>: Privacy Policy\\n⟨15⟩ https://www.aoadx.com/<https:/instagram.com/aoa_dx>:  Instagram \\n⟨16⟩ https://www.aoadx.com/<https:/www.linkedin.com/company/26216536>:  Linkedin \\n⟨17⟩ https://www.aoadx.com/<https:/twitter.com/AOA_Dx>:  Twitter \\n⟨18⟩ https://www.aoadx.com/<https:/sungraphic.com/>: Website by Sungraphic\\n' fit_markdown='' fit_html=''",
  "generated_description": "**AOA Dx: Pioneering Early Detection for Ovarian Cancer**\n\nFounded in 2020 and based in Denver, Colorado, AOA Dx is on a mission that truly matters: developing blood tests for the early detection of ovarian cancer. With a robust team of 25 professionals, this innovative company emerged from Y Combinator’s Batch S21, signaling a strong foundation in startup excellence.\n\nAt the heart of AOA Dx’s approach are two groundbreaking technologies: GlycoLocate™ and AKRIVIS GD™. GlycoLocate™ leverages a multi-omics platform to provide insights that could fundamentally change how we detect cancer at its earliest stages. On the other hand, AKRIVIS GD™ is a unique blood test that combines artificial intelligence with these novel biomarkers to pinpoint early-stage ovarian cancer, harnessing the power of lipidomics.\n\nThe founder’s ambition is palpable: create impactful and cost-effective medical technologies that transition from theoretical research to practical applications for patients and healthcare providers alike. This isn't just about innovation for the sake of it; it’s about saving lives and improving the quality of care for women facing the risk of ovarian cancer.\n\nIf you’re passionate about transformative health technologies, a career with AOA Dx could be a pivotal chance to make a difference. The company is actively looking for team members who are committed to elevating women’s health standards.\n\nThere’s a sense of urgency in what they're doing; after all, early detection can be the difference between life and death. Keep an eye on AOA Dx not just as a company, but as a potential game-changer in the healthcare diagnostics landscape.\n\nFor more details, visit their website at [AOA Dx](https://www.aoadx.com/)."
}